(PHIA) Koninklijke Philips - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0000009538
Stock:
Total Rating 49
Risk 82
Buy Signal 0.90
| Risk 5d forecast | |
|---|---|
| Volatility | 32.0% |
| Relative Tail Risk | -24.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.32 |
| Alpha | -3.54 |
| Character TTM | |
|---|---|
| Beta | 0.734 |
| Beta Downside | 0.741 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.92% |
| CAGR/Max DD | 0.89 |
EPS (Earnings per Share)
Revenue
Description: PHIA Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 895.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.48 > 1.0 |
| NWC/Revenue: 13.59% < 20% (prev 10.42%; Δ 3.17% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.17b > Net Income 895.0m |
| Net Debt (5.29b) to EBITDA (2.71b): 1.96 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (965.9m) vs 12m ago 3.49% < -2% |
| Gross Margin: 45.18% > 18% (prev 0.43%; Δ 4475 % > 0.5%) |
| Asset Turnover: 63.78% > 50% (prev 62.19%; Δ 1.59% > 0%) |
| Interest Coverage Ratio: 4.82 > 6 (EBITDA TTM 2.71b / Interest Expense TTM 328.0m) |
Altman Z'' 1.67
| A: 0.09 (Total Current Assets 9.93b - Total Current Liabilities 7.51b) / Total Assets 26.94b |
| B: 0.13 (Retained Earnings 3.58b / Total Assets 26.94b) |
| C: 0.06 (EBIT TTM 1.58b / Avg Total Assets 27.96b) |
| D: 0.25 (Book Value of Equity 4.04b / Total Liabilities 15.96b) |
| Altman-Z'' Score: 1.67 = BB |
Beneish M -3.20
| DSRI: 0.88 (Receivables 3.59b/4.12b, Revenue 17.83b/18.02b) |
| GMI: 0.95 (GM 45.18% / 43.13%) |
| AQI: 0.96 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 0.99 (Revenue 17.83b / 18.02b) |
| TATA: -0.01 (NI 895.0m - CFO 1.17b) / TA 26.94b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of PHIA shares?
As of February 27, 2026, the stock is trading at EUR 26.60 with a total of 1,404,788 shares traded.
Over the past week, the price has changed by +2.82%, over one month by +9.01%, over three months by +11.25% and over the past year by +9.14%.
Over the past week, the price has changed by +2.82%, over one month by +9.01%, over three months by +11.25% and over the past year by +9.14%.
Is PHIA a buy, sell or hold?
Koninklijke Philips has no consensus analysts rating.
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.4 | 6.7% |
| Analysts Target Price | - | - |
PHIA Fundamental Data Overview February 22, 2026
Market Cap USD = 29.71b (25.11b EUR * 1.1832 EUR.USD)
P/E Trailing = 27.7895
P/E Forward = 16.4745
P/S = 1.4082
P/B = 2.2469
P/EG = 0.3634
Revenue TTM = 17.83b EUR
EBIT TTM = 1.58b EUR
EBITDA TTM = 2.71b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.29b EUR (from netDebt column, last quarter)
Enterprise Value = 30.41b EUR (25.11b + Debt 8.09b - CCE 2.79b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.58b / Interest Expense TTM 328.0m)
EV/FCF = 43.37x (Enterprise Value 30.41b / FCF TTM 701.0m)
FCF Yield = 2.31% (FCF TTM 701.0m / Enterprise Value 30.41b)
FCF Margin = 3.93% (FCF TTM 701.0m / Revenue TTM 17.83b)
Net Margin = 5.02% (Net Income TTM 895.0m / Revenue TTM 17.83b)
Gross Margin = 45.18% ((Revenue TTM 17.83b - Cost of Revenue TTM 9.78b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 44.40%)
Tobins Q-Ratio = 1.13 (Enterprise Value 30.41b / Total Assets 26.94b)
Interest Expense / Debt = 1.35% (Interest Expense 109.0m / Debt 8.09b)
Taxrate = 15.67% (73.0m / 466.0m)
NOPAT = 1.33b (EBIT 1.58b * (1 - 15.67%))
Current Ratio = 1.32 (Total Current Assets 9.93b / Total Current Liabilities 7.51b)
Debt / Equity = 0.74 (Debt 8.09b / totalStockholderEquity, last quarter 10.96b)
Debt / EBITDA = 1.96 (Net Debt 5.29b / EBITDA 2.71b)
Debt / FCF = 7.55 (Net Debt 5.29b / FCF TTM 701.0m)
Total Stockholder Equity = 10.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 895.0m / Total Assets 26.94b)
RoE = 8.21% (Net Income TTM 895.0m / Total Stockholder Equity 10.90b)
RoCE = 8.72% (EBIT 1.58b / Capital Employed (Equity 10.90b + L.T.Debt 7.24b))
RoIC = 7.02% (NOPAT 1.33b / Invested Capital 19.00b)
WACC = 6.80% (E(25.11b)/V(33.20b) * Re(8.62%) + D(8.09b)/V(33.20b) * Rd(1.35%) * (1-Tc(0.16)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.06%
[DCF] Terminal Value 76.05% ; FCFF base≈778.2m ; Y1≈510.8m ; Y5≈233.1m
[DCF] Fair Price = 0.56 (EV 5.82b - Net Debt 5.29b = Equity 533.0m / Shares 951.3m; r=6.80% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 41.97 | EPS CAGR: 13.38% | SUE: 0.35 | # QB: 0
Revenue Correlation: 22.11 | Revenue CAGR: 7.27% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg7d=-0.000 | Chg30d=-0.113 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.51 | Chg7d=-0.001 | Chg30d=-0.005 | Revisions Net=+3 | Growth EPS=-2.9% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=1.70 | Chg7d=+0.001 | Chg30d=-0.021 | Revisions Net=+0 | Growth EPS=+12.5% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 8.6% - Earnings Yield 3.6%)
[Growth] Growth Spread = -9.4% (Analyst -4.3% - Implied 5.0%)
P/E Trailing = 27.7895
P/E Forward = 16.4745
P/S = 1.4082
P/B = 2.2469
P/EG = 0.3634
Revenue TTM = 17.83b EUR
EBIT TTM = 1.58b EUR
EBITDA TTM = 2.71b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.29b EUR (from netDebt column, last quarter)
Enterprise Value = 30.41b EUR (25.11b + Debt 8.09b - CCE 2.79b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.58b / Interest Expense TTM 328.0m)
EV/FCF = 43.37x (Enterprise Value 30.41b / FCF TTM 701.0m)
FCF Yield = 2.31% (FCF TTM 701.0m / Enterprise Value 30.41b)
FCF Margin = 3.93% (FCF TTM 701.0m / Revenue TTM 17.83b)
Net Margin = 5.02% (Net Income TTM 895.0m / Revenue TTM 17.83b)
Gross Margin = 45.18% ((Revenue TTM 17.83b - Cost of Revenue TTM 9.78b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 44.40%)
Tobins Q-Ratio = 1.13 (Enterprise Value 30.41b / Total Assets 26.94b)
Interest Expense / Debt = 1.35% (Interest Expense 109.0m / Debt 8.09b)
Taxrate = 15.67% (73.0m / 466.0m)
NOPAT = 1.33b (EBIT 1.58b * (1 - 15.67%))
Current Ratio = 1.32 (Total Current Assets 9.93b / Total Current Liabilities 7.51b)
Debt / Equity = 0.74 (Debt 8.09b / totalStockholderEquity, last quarter 10.96b)
Debt / EBITDA = 1.96 (Net Debt 5.29b / EBITDA 2.71b)
Debt / FCF = 7.55 (Net Debt 5.29b / FCF TTM 701.0m)
Total Stockholder Equity = 10.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 895.0m / Total Assets 26.94b)
RoE = 8.21% (Net Income TTM 895.0m / Total Stockholder Equity 10.90b)
RoCE = 8.72% (EBIT 1.58b / Capital Employed (Equity 10.90b + L.T.Debt 7.24b))
RoIC = 7.02% (NOPAT 1.33b / Invested Capital 19.00b)
WACC = 6.80% (E(25.11b)/V(33.20b) * Re(8.62%) + D(8.09b)/V(33.20b) * Rd(1.35%) * (1-Tc(0.16)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.06%
[DCF] Terminal Value 76.05% ; FCFF base≈778.2m ; Y1≈510.8m ; Y5≈233.1m
[DCF] Fair Price = 0.56 (EV 5.82b - Net Debt 5.29b = Equity 533.0m / Shares 951.3m; r=6.80% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 41.97 | EPS CAGR: 13.38% | SUE: 0.35 | # QB: 0
Revenue Correlation: 22.11 | Revenue CAGR: 7.27% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg7d=-0.000 | Chg30d=-0.113 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.51 | Chg7d=-0.001 | Chg30d=-0.005 | Revisions Net=+3 | Growth EPS=-2.9% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=1.70 | Chg7d=+0.001 | Chg30d=-0.021 | Revisions Net=+0 | Growth EPS=+12.5% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 8.6% - Earnings Yield 3.6%)
[Growth] Growth Spread = -9.4% (Analyst -4.3% - Implied 5.0%)